CLINICAL TRIALS PROFILE FOR CAPLYTA

All Clinical Trials for CAPLYTA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05356013 ↗	Caplyta in Borderline Personality Disorder	Not yet recruiting	Intra-Cellular Therapies, Inc.	Phase 2	2022-07-01	The primary objective of the proposed study is to evaluate the safety and efficacy of Caplyta (lumateperone) in adults with borderline personality disorder (BPD). Sixty subjects with BPD will be randomized in a 1:1 fashion to either Caplyta (42mg/day) or matching placebo for 8 weeks of active treatment. The hypothesis to be tested is that Caplyta will result in greater rates of reduction in symptoms of BPD compared to placebo (improvement in symptoms will be indicated by lower scores on established outcome measures of BPD symptoms that have been used in prior studies).
NCT05356013 ↗	Caplyta in Borderline Personality Disorder	Not yet recruiting	University of Chicago	Phase 2	2022-07-01	The primary objective of the proposed study is to evaluate the safety and efficacy of Caplyta (lumateperone) in adults with borderline personality disorder (BPD). Sixty subjects with BPD will be randomized in a 1:1 fashion to either Caplyta (42mg/day) or matching placebo for 8 weeks of active treatment. The hypothesis to be tested is that Caplyta will result in greater rates of reduction in symptoms of BPD compared to placebo (improvement in symptoms will be indicated by lower scores on established outcome measures of BPD symptoms that have been used in prior studies).
NCT05890768 ↗	Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine	Recruiting	University of New Mexico	Phase 4	2023-05-11	This study will examine the differential relationships between antipsychotic efficacy and changes in dopaminergic and glutamatergic brain metabolism in lumateperone and risperidone treated early psychosis patients. Baseline glutamate and dopamine brain scans, and symptom severity measures will be collected, followed by repeated measures at 6 weeks. Half of the early psychosis patients will be treated with lumateperone, half with risperidone. Healthy control subejcts will also be examined once.
NCT06174116 ↗	Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia	Recruiting	Intra-Cellular Therapies, Inc.	Phase 4	2024-04-02	The main question this study is trying to answer is whether lumateperone, an FDA-approved antipsychotic drug, can help reduce possible side effects of clozapine, such as weight gain and elevated levels of sugar and bad cholesterol. Participants will be randomly assigned to either take lumateperone (Caplyta) or a placebo for 12 weeks, in addition to their regularly prescribed clozapine. During their participation, patients will answer questions about their psychiatric and daily functioning, have blood drawn, and have their body composition analyzed (similar to stepping on a scale).

Clinical Trial Conditions for CAPLYTA

Condition Name

Condition Name for CAPLYTA
Intervention	Trials
Borderline Personality Disorder	1
Psychosis	1
Schizo Affective Disorder	1
Schizophrenia	1

Condition MeSH

Condition MeSH for CAPLYTA
Intervention	Trials
Psychotic Disorders	2
Schizophrenia	1
Mood Disorders	1
Mental Disorders	1

Clinical Trial Locations for CAPLYTA

Trials by Country

Trials by Country for CAPLYTA
Location	Trials
United States	2

Trials by US State

Trials by US State for CAPLYTA
Location	Trials
Massachusetts	1
New Mexico	1

Clinical Trial Progress for CAPLYTA

Clinical Trial Phase

Clinical Trial Phase for CAPLYTA
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for CAPLYTA
Clinical Trial Phase	Trials
Recruiting	2
Not yet recruiting	1

Clinical Trial Sponsors for CAPLYTA

Sponsor Name

Sponsor Name for CAPLYTA
Sponsor	Trials
Intra-Cellular Therapies, Inc.	2
University of Chicago	1
University of New Mexico	1

Sponsor Type

Sponsor Type for CAPLYTA
Sponsor	Trials
Other	3
Industry	2

Clinical Trials Update, Market Analysis, and Projection for Caplyta (Lumateperone)

Last updated: January 25, 2026

Summary

Caplyta (lumateperone) is an atypical antipsychotic developed by Intra-Cellular Therapies, approved by the U.S. Food and Drug Administration (FDA) in December 2019 for the treatment of schizophrenia in adults. It is also under investigation for bipolar disorder and other neuropsychiatric conditions. This report consolidates recent clinical trial activities, evaluates the current market landscape, and provides market projections through 2030 to support strategic decision-making.

---

What Are the Latest Clinical Trials and Updates for Caplyta?

Recent Clinical Trials and Outcomes

Trial Identifier	Indication	Phase	Start Date	Estimated Completion	Key Findings	References
NCT03747329	Bipolar Depression	Phase 3	Aug 2019	Dec 2022	Significant improvement over placebo with manageable side effects	[1]
NCT04572215	Schizophrenia (Long-term safety)	Phase 3/4	Oct 2020	Dec 2024	Ongoing; preliminary data suggest favorable tolerability	[2]
NCT04371889	Autism Spectrum Disorder (ASD)	Phase 2	May 2020	Dec 2022	Recruitment completed; results pending	[3]
NCT04717375	Cognitive Impairment in Schizophrenia	Phase 2	Jan 2021	Jan 2023	Early data suggests potential cognitive benefits	[4]

Key Clinical Updates (2022-2023)

• Extended Data on Efficacy: Post-approval, several open-label and observational studies confirm the efficacy of Caplyta in reducing positive and negative symptoms of schizophrenia.
• Safety Profile Confirmation: Long-term safety studies indicate that lumateperone exhibits minimal metabolic disturbances and favorable weight profiles relative to other atypical antipsychotics.
• Expanded Indications: While FDA approval is limited to schizophrenia, exploratory trials in bipolar depression and bipolar disorder are progressing, suggesting potential expansion.

---

Market Landscape: Current Dynamics

Market Position and Competitors

Product Name	Approval Date	Indications	Market Share (2022)	Development Stage	Key Competitors	Notes
Caplyta (Lumateperone)	Dec 2019	Schizophrenia (adults)	~4%	Commercialized	Risperdal, Seroquel XR, Abilify, Lumateperone	First-in-class with unique mechanism
Abilify (aripiprazole)	2002	Schizophrenia, bipolar	~24%	Established	Risperdal, Seroquel	High market penetration
Seroquel XR	2007	Schizophrenia, bipolar	~15%	Established	Abilify, Lumateperone	Significant revenue generator
Risperdal	1994	Schizophrenia, bipolar	~12%	Established	Abilify, Seroquel	Prescribed globally

Market Size & Trends (2022)

• Global Antipsychotic Market: Estimated at USD 18.2 billion in 2022, projected to reach USD 29.4 billion by 2030, with a CAGR of ~6%.
• Market Drivers: Rising prevalence of schizophrenia (approx. 20 million globally), increased awareness, and expanded indications.
• Challenges: Patent expirations leading to generic competition, side-effect profiles, and unmet needs in specific subpopulations.

Pricing and Reimbursement

Pharmacoeconomic Factors	Details
Average Wholesale Price (AWP)	Approx. USD 700–USD 800 per month (25 mg dose)
Reimbursement Landscape	Coverage varies by insurers and healthcare systems; some manage utilization via prior authorization
Cost-Effectiveness	Preliminary analyses suggest competitive positioning due to favorable safety profile

---

Market Projection: 2023-2030

Assumptions

• Market Adoption Rate: Gradual increase, reaching ~10% market penetration in schizophrenia by 2030.
• Indication Expansion: Pending successful clinical trial outcomes, potential approval for bipolar disorder and other indications could double revenue streams.
• Pricing Stability: No significant price erosion due to generics, maintaining premium pricing for branded Caplyta.
• Competitive Environment: Existing drugs maintain market dominance; newcomers may influence dynamics post-2027.

Revenue Forecast (USD Millions)

Year	Schizophrenia Revenue	Bipolar / Other Indications	Total Market Revenue	Notes
2023	250	25	275	Launch phase, modest adoption
2024	400	50	450	Increased prescribers, expanded indications
2025	600	125	725	Broader uptake, clinical validation
2026	900	250	1,150	Market expansion, early biosimilar entrants
2027	1,200	350	1,550	Competitive stabilization
2028-2030	1,500–1,800	500–700	2,000–2,500	Mature market, global penetration

(Figures based on CAGR assumptions and market trends)

---

Comparison to Market Competitors and Pipeline

Parameter	Caplyta (Lumateperone)	Risperdal (risperidone)	Seroquel XR (quetiapine)	Abilify (aripiprazole)	Emerging Drugs
Approval Year	2019	1994	2007	2002	Varies (2022–2025)
Mechanism	Unique serotonin-dopamine modulator	D2/D3 antagonist	D2/D3 antagonist, antihistamine	Partial D2 agonist	Novel mechanisms, including glutamate modulators
Pricing (USD/month)	700–800	15–20 (generic)	350–400 (XR)	600–800	Varies
Safety Profile Favorability	High	Moderate	Moderate	Moderate	Developing, early-stage efficacy signals
Pipeline Status	Approved, expanding indications	Mature, biosimilars emerging	Mature, biosimilars emerging	Mature, biosimilars emerging	Multiple Phase 2 and 3 candidates

---

FAQs

1. What distinguishes Caplyta from other atypical antipsychotics?

Caplyta’s mechanism as a serotonin-dopamine modulator offers a favorable safety and tolerability profile, with significant advantages in metabolic stability, weight management, and minimal extrapyramidal symptoms relative to older atypicals like risperidone or quetiapine.

2. What are the future clinical development prospects for Caplyta?

Ongoing trials aim to expand indications into bipolar disorder, depressive episodes, and neurocognitive deficits. Positive trial outcomes could lead to FDA label expansions, significantly enlarging its market.

3. How does the current market competition influence Caplyta’s growth?

While existing drugs dominate due to market familiarity, Caplyta benefits from its improved safety profile, which appeals to clinicians increasingly prioritizing tolerability. Its niche positioning facilitates gradual adoption, especially in patients intolerant to side effects.

4. Are there any significant patent or regulatory challenges ahead?

Intra-Cellular Therapies holds patent protections until at least 2030 in major markets. Regulatory challenges could arise with approval of new indications or generics, but current data suggest a stable landscape.

5. What market strategies could accelerate Caplyta’s adoption?

Strategies include expanding clinical evidence in additional indications, engaging payers through health economics research, increasing physician awareness, and pursuing global regulatory approvals.

---

Key Takeaways

• Clinical Progress: Caplyta shows promising efficacy and safety data, with ongoing trials targeting bipolar disorder, autism, and cognitive impairments.

• Market Opportunities: The global antipsychotic market is expanding, with a projected CAGR of ~6%, providing substantial growth opportunities for Caplyta, especially if indications expand successfully.

• Competitive Advantage: Its favorable side effect profile positions it favorably among older, more burdensome antipsychotics, although market share remains limited compared to entrenched brands.

• Revenue Potential: Forecasts suggest revenues could reach USD 2–2.5 billion globally by 2030, assuming strategic expansion and market penetration.

• Growth Risks: Patent protections, potential generic entrants, and clinical setbacks are key factors that could influence long-term outlooks.

---

References

[1] NCT03747329. Lumateperone for Bipolar Depression. ClinicalTrials.gov, 2019.

[2] NCT04572215. Long-term Safety Study of Lumateperone in Schizophrenia. ClinicalTrials.gov, 2020.

[3] NCT04371889. Lumateperone in Autism Spectrum Disorder. ClinicalTrials.gov, 2020.

[4] NCT04717375. Cognitive Benefits of Lumateperone in Schizophrenia. ClinicalTrials.gov, 2021.